Abstract
18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) imaging has become a clinical mainstay in the diagnosis and treatment of inflammatory cardiovascular diseases. In order to optimize the utility of this imaging technique, careful patient preparation is required to suppress normal myocardial glucose metabolism and, accordingly, 18F-FDG uptake in order to effectively distinguish background myocardium from pathologic inflammation. At present, preparation protocols are highly variable and are defined by individual institutions. Techniques that are often employed in combination include dietary (e.g., fasting, high-fat low-carbohydrate diet) and behavioral strategies (e.g., abstaining from exercise) as well as pharmacologic interventions (e.g., heparin). This chapter will review the metabolism of normal myocardium and inflammatory cells, the different patient preparation strategies and available evidence supporting their implementation, challenging patient populations, current consensus recommendations, and future directions to provide further optimization of this imaging technique.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- 18F-FDG:
-
18F-fluorodeoxyglucose
- JSNC:
-
Japanese Society of Nuclear Cardiology
- PET:
-
Positron Emission Tomography
- SNMMI/ASNC:
-
Society of Nuclear Medicine and Molecular Imaging/American Society of Nuclear Cardiology
References
Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99(4):578–88.
Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42(10):1551–5.
Osborne MT, Hulten EA, Murthy VL, Skali H, Taqueti VR, Dorbala S, et al. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol. 2017;24(1):86–99.
Morooka M, Moroi M, Uno K, Ito K, Wu J, Nakagawa T, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res. 2014;4(1):1.
Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, et al. Joint SNMMI-ASNC expert consensus document on the role of (18) F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol. 2017;24(5):1741–58.
Taegtmeyer H. Tracing cardiac metabolism in vivo: one substrate at a time. J Nucl Med. 2010;51(Suppl 1):80S–7S.
Christopoulos G, Jouni H, Acharya GA, Blauwet LA, Kapa S, Bois J, et al. Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: the effect of a structured patient preparation protocol. J Nucl Cardiol. 2019;28(2):661–71.
Kumita S, Yoshinaga K, Miyagawa M, Momose M, Kiso K, Kasai T, et al. Recommendations for (18) F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations. J Nucl Cardiol. 2019;26(4):1414–33.
Larson SR, Pieper JA, Hulten EA, Ficaro EP, Corbett JR, Murthy VL, et al. Characterization of a highly effective preparation for suppression of myocardial glucose utilization. J Nucl Cardiol. 2019;27(3):849–61.
Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol. 1979;7(5):531–3.
Demeure F, Hanin FX, Bol A, Vincent MF, Pouleur AC, Gerber B, et al. A randomized trial on the optimization of 18F-FDG myocardial uptake suppression: implications for vulnerable coronary plaque imaging. J Nucl Med. 2014;55(10):1629–35.
Alvi RM, Young BD, Shahab Z, Pan H, Winkler J, Herzog E, et al. Repeatability and optimization of FDG positron emission tomography for evaluation of cardiac sarcoidosis. JACC Cardiovasc Imaging. 2019;12(7 Pt 1):1284–7.
Osborne MT, Divakaran S. Seeking clarity: insights from a highly effective preparation protocol for suppressing myocardial glucose uptake for PET imaging of cardiac inflammation. J Nucl Cardiol. 2020;27(3):862–4.
Schelbert HR, Henze E, Phelps ME, Kuhl DE. Assessment of regional myocardial ischemia by positron-emission computed tomography. Am Heart J. 1982;103(4):588–97.
Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40(2):271–7.
Gormsen LC, Svart M, Thomsen HH, Sondergaard E, Vendelbo MH, Christensen N, et al. Ketone body infusion with 3-Hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study. J Am Heart Assoc. 2017;6(3):e005066.
Martineau P, Pelletier-Galarneau M, Juneau D, Leung E, Nery PB, de Kemp R, et al. Imaging cardiac sarcoidosis with FLT-PET compared with FDG/perfusion-PET: a prospective pilot study. JACC Cardiovasc Imaging. 2019;12(11 Pt 1):2280–1.
Bravo PE, Bajaj N, Padera RF, Morgan V, Hainer J, Bibbo CF, et al. Feasibility of somatostatin receptor-targeted imaging for detection of myocardial inflammation: a pilot study. J Nucl Cardiol. 2019;28(3):1089–99.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Osborne, M.T., Mezue, K., Divakaran, S. (2022). Myocardial Suppression Protocols. In: Pelletier-Galarneau, M., Martineau, P. (eds) FDG-PET/CT and PET/MR in Cardiovascular Diseases. Springer, Cham. https://doi.org/10.1007/978-3-031-09807-9_4
Download citation
DOI: https://doi.org/10.1007/978-3-031-09807-9_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-09806-2
Online ISBN: 978-3-031-09807-9
eBook Packages: MedicineMedicine (R0)